Rigel Pharmaceuticals Inc (RIGL) Stock Analysis
Verdict: BUY
Commercial oncology revenue expansion and positive cash flow derisk valuation, but high earnings lumpiness remains the key swing factor.
Investment score: 71/100
Analysis as of
Is Rigel Pharmaceuticals Inc stock worth reviewing? The TradeMates thesis
Rigel Pharmaceuticals demonstrates rare biotech profitability with 91.4% gross margins, 31.5% operating margins, and $75.7M FCF. Supported by three FDA-approved commercial drugs and an EV/EBITDA of 8.70x, the model identifies RIGL as an undervalued commercial growth play with consensus upside toward $67.00.
7-factor investment score
- Valuation: 78/100 (weight 20%)
- Financial Health: 85/100 (weight 15%)
- Technical Momentum: 75/100 (weight 15%)
- Earnings Quality: 55/100 (weight 15%)
- Insider Sentiment: 40/100 (weight 10%)
- Analyst Consensus: 82/100 (weight 10%)
- Risk-Adjusted Return: 72/100 (weight 15%)
Rigel Pharmaceuticals Inc opportunities and risks
What speaks for RIGL
- Commercial Triple-Engine Growth (TAVALISSE, REZLIDHIA, GAVRETO)
What speaks against RIGL
- Quarterly Revenue and EPS Volatility
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| RIGL | 2.6x | 3.0x | 8.7x | 91.4% | 116.3% | 9.5% |
| IMMX | n/a | 0.0x | n/a | 0.0% | 0.0% | -5.8% |
| OLMA | n/a | 0.0x | n/a | 0.0% | 0.0% | -18.7% |
| CADL | n/a | 0.0x | n/a | 0.0% | 0.0% | -6.9% |
| ARDX | n/a | 1.9x | n/a | 94.0% | -12.4% | -2.1% |
| GERN | n/a | 4.1x | n/a | 83.2% | -34.2% | -13.6% |
| Peer median | n/a | 0.0x | n/a | 0.0% | 0.0% | -6.9% |
Frequently asked questions about Rigel Pharmaceuticals Inc (RIGL)
Is RIGL stock a good investment?
The TradeMates model rates Rigel Pharmaceuticals Inc as BUY with an investment score of 71/100. Rigel Pharmaceuticals demonstrates rare biotech profitability with 91.4% gross margins, 31.5% operating margins, and $75.7M FCF. Supported by three FDA-approved commercial drugs and an EV/EBITDA of 8.70x, the model identifies RIGL as an undervalued commercial growth play with consensus upside toward $67.00. This is algorithmic model output, not personal investment advice.
Is RIGL stock a buy?
The TradeMates model verdict for RIGL is BUY with an investment score of 71/100. Treat this as a model signal to review, not a personal buy recommendation.